SCHEMBL21144005

SCHEMBL21144005

CSc1cc(NC2CCC(F)(F)CC2)nc(-n2nc(C)cc2C)n1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNN3 Q9UGI6 2/20 0.57
KCNN2 Q9H2S1 1/20 0.57
ALOX15 P16050 2/20 0.41
IDH1 O75874 2/20 0.40
POLB P06746 3/20 0.39
LMNA P02545 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 2/20 0.38
ALDH1A1 P00352 1/20 0.37
ADORA2A P29274 3/20 0.37
ADORA1 P30542 3/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686804 0.88 KCNN3 (0.73) KCNN3KCNN2ALOX15POLBLMNA
SCHEMBL19686521 0.84 KCNN3 (0.59) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686522 0.83 KCNN2 (0.58) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686611 0.83 KCNN2 (0.58) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686933 0.83 KCNN2 (0.57) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686803 0.83 KCNN2 (0.57) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686594 0.83 KCNN2 (0.57) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686943 0.83 KCNN2 (0.57) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686892 0.83 KCNN2 (0.57) KCNN3KCNN2ALOX15IDH1POLB
SCHEMBL19686588 0.83 KCNN2 (0.57) KCNN3KCNN2ALOX15IDH1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN3 11/4885KCNN2 5/4885ALOX15 2894/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN3 11/4885KCNN2 5/4885ALOX15 2894/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN3 11/4885KCNN2 5/4885ALOX15 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.